Description: Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden.
Home Page: www.klaria.com
Virdings AllE 2
Uppsala,
754 50
Sweden
Phone:
46 84 46 42 99
Officers
| Name | Title |
|---|---|
| Mr. Scott Boyer | CEO & Director |
| Mr. Hans Richter | Chief Financial Officer on Consultative |
| Mr. Marc Willuhn Ph.D. | Head of Chemistry, Manufacturing & Control |
| Dr. Hans Olivecrona M.D., Ph.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 1.6923 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6549 |
| Price-to-Sales TTM: | 7.4738 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |